Brigham and Women´s Hospital
Brigham and Women’s Hospital (BWH) is a teaching hospital of Harvard Medical School in Boston. It plays a leading role in patient quality and safety as well as in the development of state-of-the-art treatments and technologies. BWH provides resources integrating science, medicine, and engineering to address some of the most challenging issues in health care.
The Khademhosseini laboratory which is involved in IMMODGEL combines engineering, life sciences, statistics, mathematics and physics. Its research is based on developing micro- and nanoscale technologies using novel biomaterials and on creating systems for tissue engineering, drug discovery and cell-based biosensing. In addition, it has expertise in gradient microfluidics for cellular and drug toxicity studies and in bioprinting complex co-culture structures.
Besides, the lab has participated in several international R&D cooperations with Korea, Australia, Japan, Portugal and the UK.
Role in IMMODGEL
The Khademhosseini Lab at BWH offers its extensive experience in microfabrication and bioprinting and in the development of cell-laden tissue engineered constructs to the IMMODGEL project. Therefore, it is responsible for the development of novel technologies for microscale scaffold design. In this context, it is in charge of creating macrophage-laden structures as 3D tissue models by using a bioprinting approach.
At a later stage of the project, it will demonstrate the positive effects of macrophages on cell viability and spreading fibroblasts within co-culture systems, in order to analyse the effects of the encapsulated macrophages on angiogenesis and extracellular matrix (ECM) secretion and ultimately tissue healing.
Additionally, Khademhosseini lab has access to different facilities at MIT and Harvard University that allow the characterisation of the engineered constructs